Skip to content

Study · Systematic review · 2026

2 results

Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

Amjad MM, Khan MM, Sarwar F, Ali A, Ali M, Bakhash F, Abid H, Ibrahim F, Mustafa K, Ali DE, Fayyaz MMN, Hassan H and 6 more

Show all authors

Mian SM, Yaseen M, Qamar I, Khan AH, Ullah S, Khan BW

Diabetes, obesity & metabolism29 Sept 2026

PMID42811393 (opens in a new tab)DOI10.1111/dom.71400 (opens in a new tab)PepBankPUB-42811393
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults with overweight or obesity, mazdutide was among the dual GLP-1/glucagon receptor agonists with the largest weight-reducing effects.

    In plain wordsIn a pooled analysis of trials in adults with overweight or obesity, mazdutide was one of the two agents that lowered weight the most.

    Peptide
    Mazdutide
    Outcome
    DecreaseWeight reduction, largest effect among dual agonists
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with mazdutide and survodutide showing the largest effects.
    1 context sentence
    Summary · context
    We systematically searched PubMed, Embase, Cochrane Library, Scopus and ClinicalTrials.gov through 20 July 2026 for randomized controlled trials of mazdutide, survodutide, cotadutide, and efinopegdutide in adults with overweight/obesity (PROSPERO CRD420261456447).
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of adults with overweight or obesity, survodutide was among the dual GLP-1/glucagon receptor agonists with the largest weight-reducing effects.

    In plain wordsIn a pooled analysis of trials in adults with overweight or obesity, survodutide was one of the two agents that lowered weight the most.

    Peptide
    Survodutide
    Outcome
    DecreaseWeight reduction, largest effect among dual agonists
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with mazdutide and survodutide showing the largest effects.
    1 context sentence
    Summary · context
    We systematically searched PubMed, Embase, Cochrane Library, Scopus and ClinicalTrials.gov through 20 July 2026 for randomized controlled trials of mazdutide, survodutide, cotadutide, and efinopegdutide in adults with overweight/obesity (PROSPERO CRD420261456447).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 5 to 40Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Versions 2 to 4

    9 Oct 2026, 03:07 UTC

    The same notice was added 3 times, first on 9 Oct 2026, 03:04 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.